CATEGORY
CADTH
- ABPI
- ACE
- ACIS
- Adelaide
- Aetsa
- Agenas
- AHRQ
- AIFA
- AMNOG
- ANVISA
- AOTMiT
- AQuAS
- Behandlingsraadet
- BfArM
- Biocat
- C2H
- CADTH
- CDC
- CDE
- CMS
- COFEPRIS
- CONITEC
- Digemid
- EFPIA
- EMA
- EPF
- Eucope
- EUnetHTA
- EuropaBio
- European Commission
- Euskadi
- FDA
- FOPH
- G-BA
- Gesundheit Österreich
- HAS
- Health Technology Wales
- Healthcare Improvement Scotland
- HHS
- HIQA
- HTAi
- ICER
- IECS
- IETS
- IHE
- IHEA
- INAHTA
- IQWiG
- ISPOR
- KCE
- Medicaid
- Medicines for Europe
- MHRA
- MSP
- NECA
- NHS
- nHTA
- NICE
- NIH
- NIHO
- NIHR
- NIPH
- NSW Health
- NZa
- OHE
- OYS
- PBS
- pCPA
- Pharmac
- PhRMA
- Salute
- SBU
- Schönermark Kielhorn Collegen
- SGK
- TÄ°TCK
- TLV
- WHO
- ZonMw
- Zorginstituut Nederland
Canada Funds Rare Disease Registry Enhancements to Support Drug Evaluation
New Flexible Service Available Through Scientific Advice Program
First Time-Limited Reimbursement Recommendation Accelerates Cancer Treatment Access
Canada Releases Final Report on Appropriate Drug Use Strategy
Patient Access Enhanced: Canada Expands Rolling Review Pilot for New Drugs
Consultation on Newborn Screening Guidance Approaches
Early Access to Promising Oncology Drugs: A Look at Canada’s Successful NOC/c Policy
Enhancing Drug Assessments with Companion Diagnostics
CADTH to Include Societal Perspectives in Economic Assessments: Revolutionizing Drug Evaluations
Optimizing Laboratory Testing: CADTH and Choosing Wisely Canada Set New Standards
Canada Takes Bold Steps to Improve Drug Access and Sustainability
Fresh Insights and Recommendations from CADTH on Emergency Department Overcrowding